Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug

[News]

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

More... (http://www.news-medical.net/news/20150312/Oxis-Biotech-executes-licensing-agreement-with-MCIT-for-development-of-antibody-drug-conjugates.aspx)